WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Tuesday, September 9, 2025Time: 4:20 PM p.m. ET Morgan Stanley Annual Global Healthcare ConferenceLocation: New York, NYFormat: One-on-one meetings onlyDate: Wednesday, September 10, 2025 Stifel Virtual Immunology and Inflammation ForumLocation: Virtual Format: Presentation and one-on-one investor meetingsDate: Tuesday, September 16, 2025Time: 10:30 a.m. ET The live webcasts will be accessible via the “Investors and News” section of the Climb Bio website: https://ir.climbbio.com/. Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days. About Climb Bio, Inc.Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com. Investors and MediaCarlo Tanzi, Ph.D.Kendall Investor Relationsctanzi@kendallir.com